Does the media refer more to VRDN or KRYS?

In the previous week, Viridian Therapeutics had 3 more articles in the media than Krystal Biotech. MarketBeat recorded 10 mentions for Viridian Therapeutics and 7 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.30 beat Viridian Therapeutics' score of 1.04 indicating that Krystal Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viridian Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Krystal Biotech 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor VRDN or IONS?

In the previous week, Ionis Pharmaceuticals had 8 more articles in the media than Viridian Therapeutics. MarketBeat recorded 18 mentions for Ionis Pharmaceuticals and 10 mentions for Viridian Therapeutics. Ionis Pharmaceuticals' average media sentiment score of 1.08 beat Viridian Therapeutics' score of 1.04 indicating that Ionis Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viridian Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ionis Pharmaceuticals 9 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer VRDN or CYTK?

In the previous week, Viridian Therapeutics had 2 more articles in the media than Cytokinetics. MarketBeat recorded 10 mentions for Viridian Therapeutics and 8 mentions for Cytokinetics. Viridian Therapeutics' average media sentiment score of 1.04 beat Cytokinetics' score of 0.65 indicating that Viridian Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viridian Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cytokinetics 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to VRDN or SYRE?

In the previous week, Viridian Therapeutics had 5 more articles in the media than Spyre Therapeutics. MarketBeat recorded 10 mentions for Viridian Therapeutics and 5 mentions for Spyre Therapeutics. Viridian Therapeutics' average media sentiment score of 1.04 beat Spyre Therapeutics' score of 0.43 indicating that Viridian Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viridian Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spyre Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Viridian Therapeutics (VRDN) Competitors

$24.29 -0.21 (-0.86%)

As of 08/21/2026 04:00 PM Eastern

Compare

VRDN vs. KRYS, NUVL, IONS, CYTK, and SYRE

Should you buy Viridian Therapeutics stock or one of its competitors? Viridian Therapeutics's main competitors and comparable companies include Krystal Biotech (KRYS), Nuvalent (NUVL), Ionis Pharmaceuticals (IONS), Cytokinetics (CYTK), and Spyre Therapeutics (SYRE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Viridian Therapeutics compare to Krystal Biotech?

Viridian Therapeutics (NASDAQ:VRDN) and Krystal Biotech (NASDAQ:KRYS) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk, profitability and media sentiment.

Viridian Therapeutics has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market.

Viridian Therapeutics currently has a consensus target price of $38.93, indicating a potential upside of 60.27%. Krystal Biotech has a consensus target price of $365.40, indicating a potential upside of 5.43%. Given Viridian Therapeutics' higher possible upside, research analysts plainly believe Viridian Therapeutics is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viridian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92

Krystal Biotech has a net margin of 54.82% compared to Viridian Therapeutics' net margin of -505.86%. Krystal Biotech's return on equity of 19.34% beat Viridian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viridian Therapeutics	-505.86%	-72.97%	-42.80%
Krystal Biotech	54.82%	19.34%	17.65%

86.3% of Krystal Biotech shares are owned by institutional investors. 2.4% of Viridian Therapeutics shares are owned by insiders. Comparatively, 13.1% of Krystal Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Viridian Therapeutics had 3 more articles in the media than Krystal Biotech. MarketBeat recorded 10 mentions for Viridian Therapeutics and 7 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.30 beat Viridian Therapeutics' score of 1.04 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viridian Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Krystal Biotech	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Krystal Biotech has higher revenue and earnings than Viridian Therapeutics. Viridian Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viridian Therapeutics	$70.85M	38.84	-$342.60M	-$3.37	N/A
Krystal Biotech	$389.13M	26.36	$204.83M	$7.98	43.43

Summary

Krystal Biotech beats Viridian Therapeutics on 12 of the 17 factors compared between the two stocks.

How does Viridian Therapeutics compare to Nuvalent?

Viridian Therapeutics (NASDAQ:VRDN) and Nuvalent (NASDAQ:NUVL) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.

Viridian Therapeutics has higher revenue and earnings than Nuvalent. Nuvalent is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viridian Therapeutics	$70.85M	38.84	-$342.60M	-$3.37	N/A
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A

Viridian Therapeutics has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market. Comparatively, Nuvalent has a beta of 1.14, meaning that its share price is 14% more volatile than the broader market.

Nuvalent has a net margin of 0.00% compared to Viridian Therapeutics' net margin of -505.86%. Nuvalent's return on equity of -40.11% beat Viridian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viridian Therapeutics	-505.86%	-72.97%	-42.80%
Nuvalent	N/A	-40.11%	-35.43%

Viridian Therapeutics currently has a consensus target price of $38.93, suggesting a potential upside of 60.27%. Nuvalent has a consensus target price of $127.73, suggesting a potential upside of 3.04%. Given Viridian Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Viridian Therapeutics is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viridian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86
Nuvalent	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.15

In the previous week, Viridian Therapeutics had 10 more articles in the media than Nuvalent. MarketBeat recorded 10 mentions for Viridian Therapeutics and 0 mentions for Nuvalent. Viridian Therapeutics' average media sentiment score of 1.04 beat Nuvalent's score of 0.00 indicating that Viridian Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Viridian Therapeutics	Positive
Nuvalent	Neutral

97.3% of Nuvalent shares are owned by institutional investors. 2.4% of Viridian Therapeutics shares are owned by insiders. Comparatively, 5.0% of Nuvalent shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Viridian Therapeutics beats Nuvalent on 9 of the 15 factors compared between the two stocks.

How does Viridian Therapeutics compare to Ionis Pharmaceuticals?

Viridian Therapeutics (NASDAQ:VRDN) and Ionis Pharmaceuticals (NASDAQ:IONS) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 2.4% of Viridian Therapeutics shares are owned by company insiders. Comparatively, 1.8% of Ionis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Viridian Therapeutics has higher earnings, but lower revenue than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viridian Therapeutics	$70.85M	38.84	-$342.60M	-$3.37	N/A
Ionis Pharmaceuticals	$944M	10.52	-$381.39M	-$3.46	N/A

Viridian Therapeutics currently has a consensus target price of $38.93, indicating a potential upside of 60.27%. Ionis Pharmaceuticals has a consensus target price of $94.15, indicating a potential upside of 57.60%. Given Viridian Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Viridian Therapeutics is more favorable than Ionis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viridian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86
Ionis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.73

Ionis Pharmaceuticals has a net margin of -64.76% compared to Viridian Therapeutics' net margin of -505.86%. Viridian Therapeutics' return on equity of -72.97% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viridian Therapeutics	-505.86%	-72.97%	-42.80%
Ionis Pharmaceuticals	-64.76%	-111.08%	-17.41%

Viridian Therapeutics has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market. Comparatively, Ionis Pharmaceuticals has a beta of 0.41, indicating that its share price is 59% less volatile than the broader market.

In the previous week, Ionis Pharmaceuticals had 8 more articles in the media than Viridian Therapeutics. MarketBeat recorded 18 mentions for Ionis Pharmaceuticals and 10 mentions for Viridian Therapeutics. Ionis Pharmaceuticals' average media sentiment score of 1.08 beat Viridian Therapeutics' score of 1.04 indicating that Ionis Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viridian Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ionis Pharmaceuticals	9 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Viridian Therapeutics beats Ionis Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Viridian Therapeutics compare to Cytokinetics?

Viridian Therapeutics (NASDAQ:VRDN) and Cytokinetics (NASDAQ:CYTK) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

In the previous week, Viridian Therapeutics had 2 more articles in the media than Cytokinetics. MarketBeat recorded 10 mentions for Viridian Therapeutics and 8 mentions for Cytokinetics. Viridian Therapeutics' average media sentiment score of 1.04 beat Cytokinetics' score of 0.65 indicating that Viridian Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viridian Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytokinetics	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Viridian Therapeutics has higher earnings, but lower revenue than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viridian Therapeutics	$70.85M	38.84	-$342.60M	-$3.37	N/A
Cytokinetics	$88.04M	108.60	-$784.96M	-$7.22	N/A

Viridian Therapeutics has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market.

Viridian Therapeutics has a net margin of -505.86% compared to Cytokinetics' net margin of -1,321.12%. Cytokinetics' return on equity of 0.00% beat Viridian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viridian Therapeutics	-505.86%	-72.97%	-42.80%
Cytokinetics	-1,321.12%	N/A	-51.01%

Viridian Therapeutics currently has a consensus target price of $38.93, indicating a potential upside of 60.27%. Cytokinetics has a consensus target price of $102.20, indicating a potential upside of 33.00%. Given Viridian Therapeutics' higher probable upside, research analysts clearly believe Viridian Therapeutics is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viridian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86
Cytokinetics	1 Sell rating(s)	1 Hold rating(s)	19 Buy rating(s)	0 Strong Buy rating(s)	2.86

Summary

Viridian Therapeutics beats Cytokinetics on 9 of the 13 factors compared between the two stocks.

How does Viridian Therapeutics compare to Spyre Therapeutics?

Viridian Therapeutics (NASDAQ:VRDN) and Spyre Therapeutics (NASDAQ:SYRE) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, media sentiment, institutional ownership, risk and dividends.

Spyre Therapeutics has a net margin of 0.00% compared to Viridian Therapeutics' net margin of -505.86%. Spyre Therapeutics' return on equity of -30.74% beat Viridian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viridian Therapeutics	-505.86%	-72.97%	-42.80%
Spyre Therapeutics	N/A	-30.74%	-22.23%

In the previous week, Viridian Therapeutics had 5 more articles in the media than Spyre Therapeutics. MarketBeat recorded 10 mentions for Viridian Therapeutics and 5 mentions for Spyre Therapeutics. Viridian Therapeutics' average media sentiment score of 1.04 beat Spyre Therapeutics' score of 0.43 indicating that Viridian Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viridian Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Spyre Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Viridian Therapeutics currently has a consensus target price of $38.93, indicating a potential upside of 60.27%. Spyre Therapeutics has a consensus target price of $111.69, indicating a potential upside of 4.89%. Given Viridian Therapeutics' higher probable upside, equities analysts plainly believe Viridian Therapeutics is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viridian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86
Spyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87

Viridian Therapeutics has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 3.03, suggesting that its share price is 203% more volatile than the broader market.

Spyre Therapeutics has lower revenue, but higher earnings than Viridian Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viridian Therapeutics	$70.85M	38.84	-$342.60M	-$3.37	N/A
Spyre Therapeutics	$890K	10,522.17	-$155.20M	-$1.95	N/A

80.4% of Spyre Therapeutics shares are held by institutional investors. 2.4% of Viridian Therapeutics shares are held by insiders. Comparatively, 15.7% of Spyre Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Spyre Therapeutics beats Viridian Therapeutics on 11 of the 17 factors compared between the two stocks.

Get Viridian Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VRDN vs. The Competition

Export

Metric	Viridian Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.75B	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	-7.21	11.62	272.60	24.24
Price / Sales	38.84	1,338.17	618.96	99.81
Price / Cash	N/A	105.14	78.62	53.99
Price / Book	4.88	16.80	13.05	6.20
Net Income	-$342.60M	-$12.50M	$3.47B	$348.59M
7 Day Performance	10.01%	3.29%	2.09%	0.08%
1 Month Performance	26.12%	8.23%	6.64%	3.88%
1 Year Performance	26.31%	55.05%	25.02%	16.98%

Viridian Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VRDN Viridian Therapeutics	2.7268 of 5 stars	$24.29 -0.9%	$38.93 +60.3%	+26.3%	$2.75B	$70.85M	N/A	50	News Coverage Positive News Insider Trade
KRYS Krystal Biotech	4.1259 of 5 stars	$335.73 +1.0%	$365.40 +8.8%	+130.3%	$9.83B	$440.48M	42.07	210	Positive News Analyst Downgrade
NUVL Nuvalent	2.121 of 5 stars	$123.96 flat	$127.73 +3.0%	N/A	$9.79B	N/A	N/A	40
IONS Ionis Pharmaceuticals	3.5688 of 5 stars	$58.63 +2.4%	$94.65 +61.4%	+39.9%	$9.51B	$944M	N/A	1,402	News Coverage Positive News Analyst Upgrade Options Volume
CYTK Cytokinetics	3.3743 of 5 stars	$75.87 +2.3%	$102.20 +34.7%	+100.4%	$9.44B	$67.67M	N/A	250	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VRDN) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Viridian Therapeutics (VRDN) Competitors

VRDN vs. KRYS, NUVL, IONS, CYTK, and SYRE

How does Viridian Therapeutics compare to Krystal Biotech?

Summary

How does Viridian Therapeutics compare to Nuvalent?

Summary

How does Viridian Therapeutics compare to Ionis Pharmaceuticals?

Summary

How does Viridian Therapeutics compare to Cytokinetics?

Summary

How does Viridian Therapeutics compare to Spyre Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRDN vs. The Competition

Viridian Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Viridian Therapeutics (VRDN) Competitors

VRDN vs. KRYS, NUVL, IONS, CYTK, and SYRE

How does Viridian Therapeutics compare to Krystal Biotech?

Which has more risk & volatility, VRDN or KRYS?

Do analysts prefer VRDN or KRYS?

Is VRDN or KRYS more profitable?

Do insiders and institutionals have more ownership in VRDN or KRYS?

Does the media refer more to VRDN or KRYS?

Which has stronger earnings and valuation, VRDN or KRYS?

Summary

How does Viridian Therapeutics compare to Nuvalent?

Which has better valuation & earnings, VRDN or NUVL?

Which has more risk & volatility, VRDN or NUVL?

Is VRDN or NUVL more profitable?

Do analysts rate VRDN or NUVL?

Does the media refer more to VRDN or NUVL?

Do institutionals & insiders hold more shares of VRDN or NUVL?

Summary

How does Viridian Therapeutics compare to Ionis Pharmaceuticals?

Do institutionals and insiders believe in VRDN or IONS?

Which has higher valuation and earnings, VRDN or IONS?

Do analysts prefer VRDN or IONS?

Is VRDN or IONS more profitable?

Which has more risk & volatility, VRDN or IONS?

Does the media favor VRDN or IONS?

Summary

How does Viridian Therapeutics compare to Cytokinetics?

Does the media prefer VRDN or CYTK?

Which has stronger valuation & earnings, VRDN or CYTK?

Which has more risk & volatility, VRDN or CYTK?

Is VRDN or CYTK more profitable?

Do analysts prefer VRDN or CYTK?

Summary

How does Viridian Therapeutics compare to Spyre Therapeutics?

Is VRDN or SYRE more profitable?

Does the media refer more to VRDN or SYRE?

Do analysts prefer VRDN or SYRE?

Which has more risk and volatility, VRDN or SYRE?

Which has higher valuation and earnings, VRDN or SYRE?

Do institutionals & insiders believe in VRDN or SYRE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRDN vs. The Competition

Viridian Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools